Amgen and Allergan announced today that the companies have submitted a Biologics License Application for ABP 980, a proposed trastuzumab (Herceptin) biosimilar.
Amgen and Allergan announced today that the companies have submitted a Biologics License Application (BLA) for ABP 980, a proposed trastuzumab (Herceptin) biosimilar.
The companies’ BLA submission includes data from a phase 3 comparative efficacy, safety, and immunogenicity study conducted in adult female patients with HER2-positive early breast cancer. The partnership also filed for approval of the product with the European Union’s European Medicines Agency in March of 2017.
"The submission of ABP 980 for FDA review is an exciting milestone and speaks to our joint commitment with Allergan to deliver quality oncology biosimilars to patients," said Sean E. Harper, MD, executive vice president of research and development at Amgen. "Approval of ABP 980 would provide more patients access to a high-quality therapy with a proven safety and efficacy profile. We look forward to further discussions with the FDA."
Allergan’s chief of research and development, David Nicholson, added, "We're proud of the progress we've made so far and look forward to continuing our work to bring more biosimilars to market."
US-based Amgen and Ireland-based Allergan are collaborating on 4 biosimilar products, including ABP 980, for oncology indications. In July, the partnership received a unanimous recommendation for approval from the FDA’s Oncologic Drugs Advisory Committee (ODAC) for another of those products, ABP 215, a proposed bevacizumab (Avastin) biosimilar. The FDA’s decision on ABP 215 is expected in September.
The Amgen—Allergan partnership’s filing comes just 1 day after Celltrion and Teva announced a trastuzumab biosimilar BLA of their own. The Celltrion—Teva product, CT-P6, also relies on data from a phase 3 equivalence trial in patients with HER2-postive early breast cancer.
However, the first biosimilar trastuzumab product expected to penetrate the US market is Mylan and Biocon’s trastuzumab, MYL-1401O, which has a Biosimilar User Fee Act date of September 3, 2017. The product recently received a unanimous ODAC recommendation for approval. The Mylan—Biocon product is expected to be the first biosimilar challenger to the reference Herceptin after Mylan entered a global settlement with the reference product’s sponsor, Genetech, in March. The settlement has provided Mylan with a global license to commercialize MYL-1401O after approval.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.